265 related articles for article (PubMed ID: 31040671)
1. Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.
Clavreul A; Pourbaghi-Masouleh M; Roger E; Menei P
Int J Nanomedicine; 2019; 14():2497-2513. PubMed ID: 31040671
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.
Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy for glioblastoma.
Gerstner ER; Batchelor TT
Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
de Groot J; Reardon DA; Batchelor TT
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714460
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.
Grodzik M; Sawosz E; Wierzbicki M; Orlowski P; Hotowy A; Niemiec T; Szmidt M; Mitura K; Chwalibog A
Int J Nanomedicine; 2011; 6():3041-8. PubMed ID: 22162660
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma.
Ohlfest JR; Demorest ZL; Motooka Y; Vengco I; Oh S; Chen E; Scappaticci FA; Saplis RJ; Ekker SC; Low WC; Freese AB; Largaespada DA
Mol Ther; 2005 Nov; 12(5):778-88. PubMed ID: 16150649
[TBL] [Abstract][Full Text] [Related]
8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
9. Localized targeted antiangiogenic drug delivery for glioblastoma.
Arnone GD; Bhimani AD; Aguilar T; Mehta AI
J Neurooncol; 2018 Apr; 137(2):223-231. PubMed ID: 29327174
[TBL] [Abstract][Full Text] [Related]
10. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
12. Tricin, 4',5,7-trihydroxy-3',5'-dimethoxyflavone, exhibits potent antiangiogenic activity in vitro.
Han JM; Kwon HJ; Jung HJ
Int J Oncol; 2016 Oct; 49(4):1497-504. PubMed ID: 27498749
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
14. Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors.
Khodabakhsh F; Muyldermans S; Behdani M; Kazemi-Lomedasht F
J Drug Target; 2020 Apr; 28(4):379-385. PubMed ID: 31822133
[TBL] [Abstract][Full Text] [Related]
15. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapies for glioblastoma.
Arrillaga-Romany I; Norden AD
CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007
[TBL] [Abstract][Full Text] [Related]
17. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents.
Konson A; Pradeep S; Seger R
Cancer Res; 2010 Aug; 70(15):6247-57. PubMed ID: 20610633
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitors in tackling recurrent glioblastoma.
Hundsberger T; Reardon DA; Wen PY
Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
[TBL] [Abstract][Full Text] [Related]
19. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
